Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zymeworks Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company with common stock trading under ZYME. Recent Form 8-K reports cover operating results and financial condition, Regulation FD disclosures, executive appointments, board changes, share repurchase authorization and material agreements involving royalty interests tied to Ziihera (zanidatamab-hrii).
The filing record also includes proxy materials for annual meeting matters, including stockholder voting procedures, governance disclosures and executive compensation. These filings describe Zymeworks' licensed healthcare assets, collaboration and royalty arrangements, capital allocation actions and public-company governance structure.
Rubric Capital Management and David Rosen report a significant stake in Zymeworks Inc. They beneficially own 5,750,000 shares of Zymeworks common stock, representing 7.68% of the outstanding shares. This ownership is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
The percentage is based on 74,836,534 Zymeworks common shares outstanding as of November 4, 2025, as disclosed in the company’s Form 10-Q. Rubric Capital has shared voting and dispositive power over these shares, primarily through Rubric Capital Master Fund LP.
Morgan Stanley filed an amended Schedule 13G reporting its beneficial ownership of Zymeworks Inc. common stock. It reports beneficial ownership of 2,519,243 shares, representing 3.4% of the class as of 12/31/2025.
Morgan Stanley has shared voting power over 2,516,398 shares and shared dispositive power over 2,519,243 shares, with no sole voting or dispositive power. It states that it has ceased to be the beneficial owner of more than five percent of this class and that the securities are held in the ordinary course of business, not to change or influence control of Zymeworks.
Zymeworks Inc. insider holdings: SVP & Chief Medical Officer Mekan Sabeen filed an initial ownership report showing no directly owned common shares. Instead, the filing lists equity awards in the form of options and stock units.
Sabeen holds stock options for 192,000 common shares at an exercise price of $11.75 per share, expiring on April 20, 2035, from a grant on April 21, 2025, and options for 29,000 shares at $23.16 per share, expiring on January 11, 2036, from a grant on January 12, 2026. The filing also reports 19,000 restricted stock units that vest in four equal annual installments starting on the first anniversary of the January 12, 2026 grant.
In addition, Sabeen has performance stock units tied to total shareholder return goals, with a maximum of 32,000 shares potentially deliverable over a three-year performance period ending January 12, 2029. These PSUs can pay out at 50% to 200% of a 16,000-share target based on TSR performance and continued service.
Zymeworks Inc. executive Mark Hollywood, EVP & Chief Operating Officer, reported equity compensation activity on January 12, 2026. One third of previously granted restricted stock units vested, converting into 17,666 shares of common stock at no cost. To cover related tax withholding and fees under a mandatory “sell to cover” provision, 6,120 shares were sold at a weighted average price of $22.6735, leaving him with 132,913 common shares held directly.
He also received new awards: stock options for 70,000 shares at a $23.16 exercise price, 47,000 new RSUs, and 66,000 performance stock units. The options vest 25% after one year and the rest monthly over three years. The RSUs vest in four equal annual installments. The PSUs can deliver up to 66,000 shares based on cumulative total shareholder return goals over a three-year period ending January 12, 2029.
Zymeworks Inc. executive Hollywood Mark, EVP & Chief Operating Officer, filed an initial ownership report showing his equity stake in the company as of January 9, 2026. He directly owns 121,367 shares of common stock. In addition, he holds several stock options to buy common shares, including 80,000 options at $15.23 expiring in 2029 and other grants through 2035 at exercise prices ranging from $7 to $35.20. Mark also holds restricted stock units, with 20,000 RSUs from a January 2024 grant and 53,000 RSUs from a January 2025 grant, each RSU representing the right to receive one share of common stock upon vesting.
Zymeworks Inc. director Brian N. Cherry reported new equity awards granted on January 12, 2026. He received a stock option for 23,000 shares of common stock at an exercise price of $23.16 per share, vesting in 36 equal monthly installments starting one month after the grant date. He also received 15,400 restricted stock units (RSUs), each representing the right to receive one share of common stock upon vesting. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. Both awards are reported as directly owned following the transactions.
Zymeworks Inc. director Brian N. Cherry filed an initial ownership report stating that he does not beneficially own any of the company’s securities. As of January 12, 2026, the filing shows zero non-derivative shares of Zymeworks Inc. held and no derivative securities, such as options or warrants, beneficially owned. The filing is made as a Form 3, which discloses a director’s starting ownership position when they become subject to insider reporting rules.
Zymeworks Inc.'s EVP & Chief Medical Officer, Jeffrey T. L. Smith, reported the vesting of 17,666 restricted stock units (RSUs) on January 12, 2026, which converted into the same number of common shares at $0.00 per share. These RSUs were part of a grant made on January 10, 2025 that vests in three equal annual installments, with each RSU delivering one share of common stock upon vesting.
On the same date, 9,310 common shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under mandatory “sell to cover” provisions, and not as a discretionary sale. After these transactions, Smith beneficially owned 26,708 common shares and 35,334 RSUs, all reported as directly held.
Zymeworks Inc. director Gregory Austin Ciongoli reported new equity awards on a Form 4. On January 12, 2026, he was granted stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036.
He also received 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and these RSUs vest on January 12, 2027. All reported derivative holdings are shown as directly owned, and the filing reflects awards being acquired rather than any sale of shares.
Zymeworks Inc. director Kelvin Neu reported new equity awards in a Form 4 dated January 12, 2026. He was granted 11,500 stock options with an exercise price of $23.16 per share and 7,700 restricted stock units (RSUs), all held as direct beneficial ownership.
The stock options and RSUs both vest on January 12, 2027. Each RSU gives the right, upon vesting, to receive one share of Zymeworks common stock. These transactions reflect equity compensation to a board member rather than open-market buying or selling.